dc.date.accessioned | 2019-12-11T20:05:15Z | |
dc.date.available | 2019-12-11T20:05:15Z | |
dc.date.created | 2018-10-16T14:00:11Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Morin, Eric Sjöberg, Elin Tjomsland, Vegard Testini, Chiara Lindskog, Cecilia Franklin, Oskar Sund, Malin Öhlund, Daniel Kiflemariam, Sara Sjöblom, Tobias Claesson-Welsh, Lena . VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival. Journal of Pathology. 2018, 246, 311-322 | |
dc.identifier.uri | http://hdl.handle.net/10852/71585 | |
dc.description.abstract | Unstable and dysfunctional tumor vasculature promotes cancer progression and spread. Signal transduction by the pro‐angiogenic vascular endothelial growth factor (VEGF) receptor‐2 (VEGFR2) is modulated by VEGFA‐dependent complex formation with neuropilin 1 (NRP1). NRP1 expressed on tumor cells can form VEGFR2/NRP1 trans‐complexes between tumor cells and endothelial cells which arrests VEGFR2 on the endothelial surface, thus interfering with productive VEGFR2 signaling. In mouse fibrosarcoma, VEGFR2/NRP1 trans‐complexes correlated with reduced tumor vessel branching and reduced tumor cell proliferation. Pancreatic ductal adenocarcinoma (PDAC) strongly expressed NRP1 on both tumor cells and endothelial cells, in contrast to other common cancer forms. Using proximity ligation assay, VEGFR2/NRP1 trans‐complexes were identified in human PDAC tumor tissue, and its presence was associated with reduced tumor vessel branching, reduced tumor cell proliferation, and improved patient survival after adjusting for other known survival predictors. We conclude that VEGFR2/NRP1 trans‐complex formation is an independent predictor of PDAC patient survival. | |
dc.language | EN | |
dc.publisher | Longman | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival | |
dc.type | Journal article | |
dc.creator.author | Morin, Eric | |
dc.creator.author | Sjöberg, Elin | |
dc.creator.author | Tjomsland, Vegard | |
dc.creator.author | Testini, Chiara | |
dc.creator.author | Lindskog, Cecilia | |
dc.creator.author | Franklin, Oskar | |
dc.creator.author | Sund, Malin | |
dc.creator.author | Öhlund, Daniel | |
dc.creator.author | Kiflemariam, Sara | |
dc.creator.author | Sjöblom, Tobias | |
dc.creator.author | Claesson-Welsh, Lena | |
cristin.unitcode | 185,53,48,10 | |
cristin.unitname | Avdeling for gastro- og barnekirurgi | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.cristin | 1620813 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal of Pathology&rft.volume=246&rft.spage=311&rft.date=2018 | |
dc.identifier.jtitle | Journal of Pathology | |
dc.identifier.volume | 246 | |
dc.identifier.startpage | 311 | |
dc.identifier.endpage | 322 | |
dc.identifier.doi | https://doi.org/10.1002/path.5141 | |
dc.identifier.urn | URN:NBN:no-74711 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 0022-3417 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/71585/1/Morin_et_al-2018-The_Journal_of_Pathology.pdf | |
dc.type.version | PublishedVersion | |